Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Stem Cell Mobilization & Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CXCR4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery (ORF) | CXCR4 Promise-ORF / Lentivirus – full-length ORF for stable cell lines preserving native GPCR conformation. | View CXCR4 Products |
| Gene Delivery (Pre-made) | CXCR4 Premade Lentivirus Particles – ready-to-use native glycosylated membrane expression. | View CXCR4 Products |
| Antigen (ECD-Fc) | CXCR4 ECD-Fc / Mutant Protein – high purity (>95%), endotoxin <1EU/μg, sequence verified. | View CXCR4 Products |
| Antigen (Full-Length) | CXCR4 Full-Length Lentivirus – HEK293 expressed, native glycosylation, endotoxin <1EU/μg. | View CXCR4 Products |
| Benchmark Ab | Anti-CXCR4 (Sequence of Ulocuplumab) – recombinant positive control for binding and flow cytometry assays. | View CXCR4 Products |
| Validator | CXCR4 siRNA Set – for knockdown verification and specificity control in cell-based assays. | View CXCR4 Products |
| Related Target A | CXCL12 (SDF-1) – endogenous ligand for chemotaxis and receptor internalization assays, high purity (>95%). | View CXCL12 Products |
| Related Target B | CXCR7 (ACKR3) – alternative receptor for CXCL12; critical for off-target selectivity screening. | View CXCR7 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity of GPCRs | Lentivirus Premade Particles enable stable, native-state membrane expression. |
| Subfamily Counter Screening (CXCR7) | Homolog panel reagents available with sequence-verified exactitude. |
| Lack of Reliable Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay baseline setting. |
| False Positives in Flow Cytometry | Validated siRNA included for specificity checks and background noise reduction. |
Live CXCR4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CXCR4/CD184 therapeutics is intensifying, with major players shifting focus from traditional small molecule antagonists (like Plerixafor) to monoclonal antibodies, peptides, and radioligands. As first-generation therapies for stem cell mobilization reach the clinic, the next wave of R&D is targeting the tumor microenvironment (TME), leukemia, and precision radiotherapeutics for metastatic solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule / Peptide | Sanofi, BioLineRx | Stem Cell Mobilization | Receptor Binding Assay (Need Native-state Lentivirus Cells) |
| Monoclonal Antibodies | BMS, Lilly | Multiple Myeloma, Solid Tumors | Epitope Mapping & Flow Cytometry (Need Benchmark Abs) |
| Radioligand Therapy | Novartis, Pentixapharm | Hematological Malignancies | Internalization Assay (Need High-Purity Controls) |
| Bispecifics | Various | Immunotherapy | Selectivity Assay (Need CXCR7 Counter-screens) |